key: cord-0837822-9cghz87o
authors: Angkasekwinai, N.; Niyomnaitham, S.; Sewatanon, J.; Phumiamorn, S.; Sukapirom, K.; Senawong, S.; Mahasirimongkol, S.; Toh, Z. Q.; Umrod, P.; Somporn, T.; Chumpol, S.; Ritthitham, K.; Chokephaibulkit, K.
title: The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
date: 2021-11-30
journal: nan
DOI: 10.1101/2021.11.29.21266947
sha: 307dfcb3d333f5f98f0906c216dd76a02b1accb1
doc_id: 837822
cord_uid: 9cghz87o

The appropriate COVID-19 booster vaccine following inactivated or adenoviral vector COVID-19 vaccination is unclear. We evaluated the safety and immunogenicity of different booster vaccines, inactivated (BBIBP-CorV), chimpanzee adenoviral vector (ChAdOx1), or mRNA (BNT162b2 at full (30 g), or half (15 g) dose) in healthy adults who received 2-dose primary series of either inactivated vaccine (CoronaVac) or ChAdOx1 8-12 weeks earlier. Overall, the adverse events for all booster vaccines were mild and moderate. Two weeks post-booster dose, the neutralising antibody titres against Delta variant in CoronaVac-prime and ChAdOx1-prime were highest with for 30g-BNT162b2 (411 vs 470) and 15g-BNT162b2 (499 vs 358); followed by ChAdOx1 (271 vs 69), and BBIBP-CorV (61.3 vs 49). BNT162b2 also induced higher interferon gamma response. Heterologous COVID-19 boosting vaccination with BNT162b2 is the most immunogenic following CoronaVac or ChAdOx1 primary series. A lower dose BNT162b2 may be used as booster in settings with limited vaccine supply.

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2021. ; https://doi.org/10.1101/2021.11.29.21266947 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 49 50 51 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ( Table 1) . Interestingly, none of the study 166 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2021. ; https://doi.org/10.1101/2021.11.29.21266947 doi: medRxiv preprint participants who were IGRA-negative at baseline in theChAdOx1-prime group had a positive 167 IGRA response following boosting with BBIBP-CorV or ChAdOx1 ( Table 1) In this study, we found that BBIBP-CorV, ChAdOx1, BNT162b2 (standard and reduced 172 dosage) given as booster dose to individuals who received either CoronaVac or ChAdOx1 primary 173 series were safe and immunogenic. BNT162b2 as a booster vaccine induced the highest humoral 174 and cellular immunity compared to BBIBP-CorV or ChAdOx1. An interesting observation was 175 the higher immune responses in the CoronaVac-primed group compared to the ChAdOx1-prime 176 group when boosting with BNT162b2 at the similar interval after primary series. 177

Booster vaccinations using BBIBP-CorV, ChAdOx1, BNT162b2 (standard and reduced 178 dosage) was safe and well tolerated, although the overall proportion who reported AEs (61-98%) 179 were high, particularly among BNT162b2 recipients, as well as among ChAdOx1 who received it 180 as the first time among CoronaVac-prime group. All AEs were mild or moderate in severity and 181 no serious AEs was reported. These AEs rates were similar to those reported in COVID-19 vaccine 182 primary series and booster studies 17-18 . The AEs frequencies following ChAdOx1 and BBIBP-183

CorV in this study were consistent with those reported in the primary series vaccination in this 184 population 7 . 185

Heterologous boosting vaccination in our study were found to be more immunogenic than 186 homologous boosting regimen of ChAdOx1 or homologous vaccine platforms (CoronaVac prime-187 BBIBP-CorV boost; inactivated vaccines). The higher humoral immune responses following 188 heterologous ChAdOx1 prime-BNT162b2 boost vaccination compared to homologous ChAdOx1 189 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint While neutralising antibodies are thought to be the primary mechanism of protection 7 , 201 virus-specific memory T cells are also important for protection. Only a third of ChAdOx1-prime 202 and a quarter of CoronaVac-prime participants in our study had positive IGRA 8-12 weeks post 203 primary series, suggesting that CoronaVac induce a poorer T cell memory response than 204 ChAdOx1. Previous studies evaluating 2-dose ChAdOx1 primary series have reported the 205 generation of robust T cell responses (measured by interferon gamma ELISPOT) 14 days 206 following the first dose, with no significant increase in T cell responses following the second 207 dose 20-21 . The discrepancy in T cell responses from our study could be due to waning immunity, 208 population differences and the different assays used to measure interferon gamma response 209 (Quantiferon vs inteferon gamma ELISPOT). Interestingly, boosting with standard or reduced 210 dosage BNT162b2 induce robust T cell responses, whereas boosting with BBIBP or homologous 211 boosting regimen of ChAdOx1 (third dose) appears to be a poor inducer of T cell responses. It is 212 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Our findings in both vaccine-prime groups suggested that less amount of antigen may be 220 sufficient for boosting. We found that half-dose of 15 µg BNT162b2 was equally immunogenic as 221 the standard dose of 30 µg, but with less reactogenicity. This is in concordance with a study on 222 mRNA1273 vaccine where a booster dose of mRNA1273 vaccine at half the normal dosage (50 223 µg) was able to induce significantly higher neutralising antibodies than the level induced following 224 primary series and against the VOCs 17 . Taken together, a lower mRNA vaccine dose may be an 225 option for COVID-19 booster vaccination given the limited vaccine supply. However, the 226 persistence of immunity and the efficacy following reduced dosages in booster vaccination 227 remains to be determined. 228

There are some limitations in this study. First, our study was conducted in an open label 229 manner due to the availability of each vaccine at a different timing. While this may lead to selection 230 bias and subjective outcomes such as AEs, the demographic characteristics of the participants in 231 the booster groups were very similar, suggesting that this is unlikely to influence our findings. 232

Second, our sample size is small, particularly those who received BBIBP as booster, and therefore, 233 the data need to be interpreted with caution. Furthermore, it is unclear if similar findings will be 234 found if the duration between the last dose of primary series and the booster dose is >12 weeks (8-235 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2021. ; https://doi.org/10.1101/2021.11.29.21266947 doi: medRxiv preprint 12 weeks in this study). Last, the participants in this study were healthy adults therefore results 236 may not be generalisable to other populations such as elderly or those with underlying diseases. 237

In conclusion, we found that a booster dose of BNT162b2 given to individuals previously 238 vaccinated with CoronaVac or ChaAdOx1 primary series is the most immunogenic. study procedures, risks, and benefits were explained to all participants before obtaining written 256 informed consent. The study protocol was approved by the Siriraj Institutional Review Board 257 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The participants were observed for at least 30 min following vaccination for any immediate 270 adverse events (AE). Participants were instructed to record self-assessment signs or symptoms in 271 an electronic diary (eDiary) for seven days after vaccination to track AE including solicited local 272 and systemic adverse reactions. An AE in this study will be defined as any unfavorable or 273 unexpected sign, symptom, or disease (including an unexpected finding in a laboratory evaluation) 274 that occurs in any participant whether it is related to the vaccination product. Solicited local AE 275 included pain, erythema, and swelling/induration at the injection site, and localized axillary 276 swelling or tenderness ipsilateral to the injection arm. Solicited systemic AE were headache, 277 fatigue, myalgia, arthralgia, nausea, vomiting, rash, fever, and chills. The severity of solicited AE 278 were graded using a numerical scale from 1 to 4 based on two guides; Toxicity Grading Scale for 279

Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials from the 280 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2021. ; https://doi.org/10.1101/2021.11.29.21266947 doi: medRxiv preprint 10 5 cells/well/ 3 ml and placed in 37°C, 5% CO2 incubator for 1 day. Test sera were initially diluted 304 at 1:10, 1:40, 1:160 and 1:640, respectively. SARS-CoV-2 virus was diluted in culture medium to 305 yield 40-120 plaques/well in the virus control wells. Cell control wells, convalescent patient serum 306 and normal human serum were also included as assay controls. The neutralisation was performed 307 by mixing the equal volume of diluted serum and the optimal plaque numbers of SARS CoV-2 308 virus at 37˚C in water bath for 1 h. After removing the culture medium from Vero cell culture 309 plates, 200 ul of the virus-serum antibody mixture were inoculated into monolayer cells and then 310 rocked the culture plates every 15 min for 1 h. Three ml of overlay semisolid medium (containing 311 1% of carboxymethylcellulose, Sigma Aldrich, USA, with 1% of 10,000 units/ml penicillin, 312 10,000 ug/ml streptomycin (Sigma, USA), and 10% FBS) were replaced after removing excessive 313 viruses. All plates were incubated at 37˚C, 5% CO2 for 7 days. Cells were fixed with 10% (v/v) 314 formaldehyde then stained with 0.5% crystal violet in PBS. The number of plaques formed was 315 counted in triplicate wells and percentage of plaque reduction at 50% (PRNT50) was calculated. 316

The PRNT50 titre of test sample is defined as the reciprocal of the highest test serum dilution for 317 which the virus infectivity is reduced by 50% when compared with the average plaque counts of 318 the virus control and was calculated by using a four-point linear regression method. Plaque counts 319 for all serial dilutions of serum were scored to ensure that there was a dose response. 320

QuantiFERON SARS-CoV-2 interferon gamma release assay (IGRA) 321 SARS-CoV-2 specific T cell responses were assessed by whole blood IGRA using 322 QIAGEN's proprietary mixes of SARS-CoV-2 S protein following manufacture's instruction. 323

Briefly, whole blood samples were collected into the unstimulated tube as negative control and 324 stimulated tubes containing SARS-CoV-2 S peptide designed for CD4 + T cell (Ag.1), for CD8 + T 325 cells (Ag.2) and for mitogen as positive control. The specimen was incubated at 37 ͦ C for 16-24 326 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All authors declare no personal or professional conflicts of interest, and no financial 370 support from the companies that produce and/or distribute the drugs, devices, or materials 371 described in this report. 372 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The PRNT50 titre of 1:5 was used for all that were below the detectable level (< 1:10). Ratio 507 paired t test was used for statistical analyses. 508 509 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2021. ; https://doi.org/10.1101/2021.11.29.21266947 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

*The post primary series GMC was derived from the study in the same setting as the current study 620 (Reference: Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against 621 the SARS-CoV-2 Circulating Variants of Concern

The post primary series GMC 623 (95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted November 30, 2021. ; https://doi.org/10.1101/2021.11.29.21266947 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2021. ; https://doi.org/10.1101/2021.11.29.21266947 doi: medRxiv preprint